Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 12, 2013

Life Technologies’ Latest Acquisition Targets Growth Markets

  • Life Technologies has taken over KDR Biotech, a South Korea-based reagents distributor that has served in that role in for Life Technologies since 1982.

    “The acquisition of KDR Biotech is in line with Life's Asia-Pacific Japan strategy to further develop customer relationships, improve the customer experience, and increase revenue in the fast-growing South Korean biotechnology market,” said Mark Smedley, president of Life Technologies, Asia-Pacific Japan region. “This is in addition to Life's overall strategy of expanding our footprint into strong growth and emerging markets.”

    KDR Biotech offers products for the academic and government research markets as well as for the bioindustry. Life will continue to offer non-Life products which had been part of KDR Biotech's portfolio, such as plastic ware and other complementary life science products.

    All current KDR Biotech employees in the main office in Seoul and throughout Korea will become part of Life Technologies Korea, according to Life officials. Jong-moon (Arnold) Kim, CEO of KDR Biotech, will serve as an external advisor to Life Technologies during the transition.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »